s6y

Kyverna Therapeutics, Inc.

Ticker
KYTX
CIK
1994702
Industry
Biological Products, (No Diagnostic Substances)
Formerly
Kyverna Therapeutics, Inc.

Financials 12

  1. 10-Q Quarterly Report for period ending Sep 30, 2026
  2. 10-Q Quarterly Report for period ending Jun 30, 2026
  3. 10-Q Quarterly Report for period ending Mar 31, 2026
  4. 10-K Annual Report for period ending Dec 31, 2025
  5. 10-Q Quarterly Report for period ending Sep 30, 2025
  6. 10-Q Quarterly Report for period ending Jun 30, 2025
  7. 10-Q Quarterly Report for period ending Mar 31, 2025
  8. 10-K Annual Report for period ending Dec 31, 2024
  9. 10-Q Quarterly Report for period ending Sep 30, 2024
  10. 10-Q Quarterly Report for period ending Jun 30, 2024

All 12 financials filings

News 42

  1. 8-K Current report filing
  2. 8-K Current report filing
  3. 8-K Current report filing
  4. 8-K Current report filing
  5. 8-K Current report filing
  6. 8-K Current report filing
  7. 8-K Current report filing
  8. 8-K Current report filing
  9. 8-K Current report filing
  10. 8-K Current report filing

All 42 news filings

Ownership 74

  1. 4 Statement of changes in beneficial ownership of securities
  2. 4 Statement of changes in beneficial ownership of securities
  3. 4 Statement of changes in beneficial ownership of securities
  4. 4 Statement of changes in beneficial ownership of securities
  5. 4 Statement of changes in beneficial ownership of securities
  6. 3 Initial statement of beneficial ownership of securities
  7. 4 Statement of changes in beneficial ownership of securities
  8. 4 Statement of changes in beneficial ownership of securities
  9. 3 Initial statement of beneficial ownership of securities
  10. 4 Statement of changes in beneficial ownership of securities

All 74 ownership filings

Prospectus 22

  1. 424B5 Prospectus filed pursuant to Rule 424(b)(5)
  2. S-8 Initial registration statement for securities to be offered to employees pursuant to employee benefit plans
  3. S-3 Registration statement for specified transactions by certain issuers
  4. 424B5 Prospectus filed pursuant to Rule 424(b)(5)
  5. FWP Filing under Securities Act Rules 163/433 of free writing prospectuses
  6. 424B5 Prospectus filed pursuant to Rule 424(b)(5)
  7. 424B5 Prospectus filed pursuant to Rule 424(b)(5)
  8. S-8 Initial registration statement for securities to be offered to employees pursuant to employee benefit plans
  9. S-3 Registration statement for specified transactions by certain issuers
  10. S-8 Initial registration statement for securities to be offered to employees pursuant to employee benefit plans

All 22 prospectus filings

Proxies 4

  1. DEFA14A Definitive additional proxy soliciting materials including Rule 14(a)(12) material. Note: Submission type DEFA14A can be filed as part of Form 8-K. For filers subject to 8-K filing requirements, we recommend the use of the 8-K combined form type as the easiest method for fulfilling your filing requirement for both forms.
  2. DEF 14A Definitive proxy statements
  3. DEFA14A Definitive additional proxy soliciting materials including Rule 14(a)(12) material. Note: Submission type DEFA14A can be filed as part of Form 8-K. For filers subject to 8-K filing requirements, we recommend the use of the 8-K combined form type as the easiest method for fulfilling your filing requirement for both forms.
  4. DEF 14A Definitive proxy statements

Other 36

  1. SCHEDULE 13G/A
  2. SCHEDULE 13G
  3. SCHEDULE 13G/A
  4. SCHEDULE 13G
  5. 144 Filing for proposed sale of securities under Rule 144
  6. 144 Filing for proposed sale of securities under Rule 144
  7. ARS Annual report to security holders
  8. 144 Filing for proposed sale of securities under Rule 144
  9. EFFECT Notice of Effectiveness
  10. 144 Filing for proposed sale of securities under Rule 144

All 36 other filings